Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Revenue (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Revenue for 16 consecutive years, with $756217.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Revenue fell 31.26% year-over-year to $756217.0, compared with a TTM value of $4.1 million through Sep 2025, down 26.92%, and an annual FY2024 reading of $4.5 million, down 35.41% over the prior year.
  • Revenue was $756217.0 for Q3 2025 at China Pharma Holdings, down from $1.0 million in the prior quarter.
  • Across five years, Revenue topped out at $2.9 million in Q4 2022 and bottomed at $756217.0 in Q3 2025.
  • Average Revenue over 5 years is $1.7 million, with a median of $1.6 million recorded in 2022.
  • The sharpest move saw Revenue soared 33.7% in 2021, then crashed 47.25% in 2024.
  • Year by year, Revenue stood at $2.9 million in 2021, then increased by 1.09% to $2.9 million in 2022, then decreased by 26.41% to $2.1 million in 2023, then tumbled by 47.25% to $1.1 million in 2024, then plummeted by 33.31% to $756217.0 in 2025.
  • Business Quant data shows Revenue for CPHI at $756217.0 in Q3 2025, $1.0 million in Q2 2025, and $1.1 million in Q1 2025.